Flash Sell! This Eye Disease Company Doesn’t Make the Cut
In the world of biotech, clinical trials can be make or break. A drug developer can have the soundest theory, the best science, and the most thorough pre-clinical testing but it still has to have a product stand up to a real world test in humans. Sometimes it does, and sometimes it doesn’t. For our eye disease company it was the latter…
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.